IL105081A - Monoclonal antibody against gangliosides, its preparation and use as a diagnostic drug or against malignant diseases - Google Patents

Monoclonal antibody against gangliosides, its preparation and use as a diagnostic drug or against malignant diseases

Info

Publication number
IL105081A
IL105081A IL105081A IL10508193A IL105081A IL 105081 A IL105081 A IL 105081A IL 105081 A IL105081 A IL 105081A IL 10508193 A IL10508193 A IL 10508193A IL 105081 A IL105081 A IL 105081A
Authority
IL
Israel
Prior art keywords
mab
antibody
ser
gqlb
monoclonal
Prior art date
Application number
IL105081A
Other languages
English (en)
Hebrew (he)
Other versions
IL105081A0 (en
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of IL105081A0 publication Critical patent/IL105081A0/xx
Publication of IL105081A publication Critical patent/IL105081A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL105081A 1992-03-19 1993-03-17 Monoclonal antibody against gangliosides, its preparation and use as a diagnostic drug or against malignant diseases IL105081A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4208795A DE4208795A1 (de) 1992-03-19 1992-03-19 Monoklonaler anti-gangliosid-antikoerper, seine herstellung und verwendung als tumortherapeutikum

Publications (2)

Publication Number Publication Date
IL105081A0 IL105081A0 (en) 1993-07-08
IL105081A true IL105081A (en) 1998-01-04

Family

ID=6454438

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105081A IL105081A (en) 1992-03-19 1993-03-17 Monoclonal antibody against gangliosides, its preparation and use as a diagnostic drug or against malignant diseases

Country Status (12)

Country Link
US (1) US5730981A (ja)
EP (1) EP0561183B1 (ja)
JP (1) JP3513173B2 (ja)
KR (1) KR100280948B1 (ja)
AT (1) ATE169962T1 (ja)
AU (1) AU666707B2 (ja)
CA (1) CA2091967C (ja)
DE (2) DE4208795A1 (ja)
DK (1) DK0561183T3 (ja)
ES (1) ES2121881T3 (ja)
IL (1) IL105081A (ja)
NO (1) NO315089B1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038252T2 (de) * 1999-09-30 2009-03-19 Kyowa Hakko Kogyo Co., Ltd. Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
EP1349567A4 (en) * 2000-12-08 2005-10-12 Childrens Memorial Hospital COMPOSITIONS WITH GANGLIOSIDES FOR USE IN THE TREATMENT OF SKIN DISEASES
KR100517613B1 (ko) * 2003-03-31 2005-09-28 엘지전자 주식회사 증기분사식 드럼세탁기
EP1684076B1 (en) 2003-10-29 2008-12-31 Kumamoto Technology & Industry Foundation Diagnostic method for malignant melanoma
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
US10752670B2 (en) * 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
CA1339798C (en) * 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
US5055559A (en) * 1986-02-20 1991-10-08 Oncogen Anti-melanoma antibody MG-21 for diagnosis and therapy of human tumors
EP0234122A3 (en) * 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
JP2789469B2 (ja) * 1988-07-16 1998-08-20 メクト株式会社 ガングリオシドＧＱ▲下１▼▲下ｂ▼およびＧＴ▲下１▼▲下ａ▼を認識するモノクローナル抗体
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
ES2098304T3 (es) * 1990-11-30 1997-05-01 Kyowa Hakko Kogyo Kk Anticuerpos monoclonales frente a cadenas de hidratos de carbono glucolipidicas.

Also Published As

Publication number Publication date
EP0561183A1 (de) 1993-09-22
EP0561183B1 (de) 1998-08-19
KR930019820A (ko) 1993-10-19
JP3513173B2 (ja) 2004-03-31
KR100280948B1 (ko) 2001-04-02
ES2121881T3 (es) 1998-12-16
CA2091967A1 (en) 1993-09-20
ATE169962T1 (de) 1998-09-15
AU666707B2 (en) 1996-02-22
US5730981A (en) 1998-03-24
IL105081A0 (en) 1993-07-08
CA2091967C (en) 2006-11-07
DE59308875D1 (de) 1998-09-24
AU3531893A (en) 1993-09-23
DK0561183T3 (da) 1999-05-25
NO930990L (no) 1993-09-20
DE4208795A1 (de) 1993-09-23
NO315089B1 (no) 2003-07-07
NO930990D0 (no) 1993-03-18
JPH0646882A (ja) 1994-02-22

Similar Documents

Publication Publication Date Title
CA2210620C (en) Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
EP3756691A1 (en) Anti-cd123 antibodies and conjugates thereof
Routledge et al. A humanized monovalent CD3 antibody which can activate homologous complement
AU2007324509B2 (en) Novel antiproliferation antibodies
US6024955A (en) Peptides and monoclonal antibodies
WO2014065402A1 (ja) 抗ヒトｃｄ４０モノクローナル抗体及びその利用
WO2014065403A1 (ja) 抗ヒトｃｄ４０モノクローナル抗体及びその利用
US5952471A (en) Antibody that binds to cluster w-4 polypeptide of human small cell lung carcinoma cells
Xu et al. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells
EP4209512A1 (en) Development of drug therapeutic agent containing adaptor and use thereof
US5730981A (en) Monoclonal anti-ganglioside antibody and its preparation
KR970007783B1 (ko) 특이적 결합제
TW202330629A (zh) 包含ＳＩＲＰα突變體的融合蛋白
WO2019078697A2 (ko) 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물
CA2080260C (en) Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof
Dubey et al. Unique proliferation-associated marker expressed on activated and transformed human cells defined by monoclonal antibody
AU669870B2 (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
WO1992021767A1 (en) Me20: monoclonal antibodies and antigen for human melanoma
CN113307871B (zh) 新型抗cd19抗体和cd19-car-t细胞的制备及其应用
Hall et al. Establishment, molecular rescue, and expression of 123AV16-1, a tumor-reactive human monoclonal antibody
CN116135885A (zh) 靶向cd73蛋白的融合蛋白
CN118546252A (zh) 抗trem2抗体及其用途

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired